Floatz logo

22 assets in Primary Sclerosing Cholangitis

Therapeutic assets addressing Primary Sclerosing Cholangitis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Vancomycin
Primary Sclerosing Cholangitis
Tampere University HospitalP4BB (71)
Aldafermin
Primary Sclerosing Cholangitis
NGM Biopharmaceuticals, IncP2/3B (62)
Elafibranor
Primary Sclerosing Cholangitis
IpsenP3B (62)
cs0159
Primary Sclerosing Cholangitis
Cascade Pharmaceuticals, IncP2B (58)
Fenofibrate
Primary Sclerosing Cholangitis
Mayo ClinicP2B (58)
hk-660s
Primary Sclerosing Cholangitis
CuromeBiosciencesP2B (57)
Norursodeoxycholic Acid
Primary Sclerosing Cholangitis
Dr. Falk Pharma GmbHP3B (57)
Simvastatin
Primary Sclerosing Cholangitis
Annika BergquistP3B (57)
Aramchol Meglumine
Primary Sclerosing Cholangitis
Galmed Pharmaceuticals LtdP2CCC (53)
brs201
Primary Sclerosing Cholangitis
Brigham and Women's HospitalP2CCC (53)
Human Faecal Matter
Primary Sclerosing Cholangitis
University of BirminghamP2CCC (53)
Hymecromone
Primary Sclerosing Cholangitis
Aparna GoelP2CCC (53)
Lb-P8
Primary Sclerosing Cholangitis
LISCure BiosciencesP2CCC (53)
Ritivixibat
Primary Sclerosing Cholangitis
Albireo, an Ipsen CompanyP2CCC (53)
Volixibat
Primary Sclerosing Cholangitis
Mirum Pharmaceuticals, Inc.P2CCC (53)
Orbcel-C
Primary Sclerosing Cholangitis
University of BirminghamP1/2CCC (48)
Tak-781
Primary Sclerosing Cholangitis
TakedaP1CC (41)
[68ga]ga-dota-cys-ath001
Primary Sclerosing Cholangitis
Antaros MedicalEarly P1C (39)
Amoxicillin
Primary Sclerosing Cholangitis
University of MinnesotaEarly P1C (38)
Rosuvastatin
Primary Sclerosing Cholangitis
Stanford UniversityEarly P1C (38)
Siplizumab
Primary Sclerosing Cholangitis
Elizabeth C. VernaP1C (33)
Norucholic Acid
Primary Sclerosing Cholangitis
Dr. Falk Pharma GmbHP3NR ()